SYNCHRO. Evaluation of the Forecasts Parameters of Real Time-three-dimensional Doppler Echocardiography in Selecting Patients With Chronic Heart Failure for Cardiac Resynchronisation Therapy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Study Classification

INTERVENTIONAL

Study Start Date

2006-11-30

Study Completion Date

2009-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Patients showing a normal value of SDI (\< or + 8%) will randomly be assigned to CRT in "ON" or "OFF"mode at one month after implantation. In any case of emergency, an automated rescue mode is included in the device for the patients in "OFF" mode.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients with a pathological SDI (\> 8%) will as usually be treated by CRT and will serve as control group. The study duration for each patient included in the trial is 6 months. Patients showing a decreased NYHA score by at least one class and an absence of major cardiovascular event during the period will be considered as "good responders". The otherswill be considered as "no responders".

Based on this composite clinical score, the percentage of good responders in each group at 6 months is the primary endpoint of the study.

Main secondary endpoints :

* Evaluation of the left ventricular function
* Exercice capacity
* Serious adverse events'frequency
* Quality of life (SF36)
* Diagnostic and prognostic value of the "Brain Natriuretic Peptide"(NT pro BNP)evolution.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Chronic Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

SINGLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Doppler echocardiography

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Both gender
* Age\>18 years
* Patients in functional class NYHA III or IV
* Patient with ejection fraction \<or=150msec or with QRS between 120 and 149 msec but with echocardiographic evidences for cardiac dyssynchrony, such as those retained in the CARE-HF trial, e.g.two from the three following criterions :-Aortic pre-ejection delay\>140msec
* Interventricular mechanical delay \>40msec
* Delayed activation of the left ventricular postero-lateral wall
* Patient under optimal treatment for chronic heart failure for at least one month before inclusion
* Written informed consentement

Exclusion Criteria

* Patient with atrial fibrillation
* Absence of echogenicity
* Patient with an indication for pacemaker implantation
* Patient suffering from arterial pressure disorders, with systolic pressure greater than 170 or lower than 80 mmHg
* Major cardiovascular event within 6 weeks before inclusion
* Patient in the exclusion period of any other clinical trial
* Patient without social insurance policy
* Drug or alcohol addiction
* Any psychological disorder
* Pregnant women
* Patient with a transplanted organ
* HIV positive serology at inclusion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Cardiac surgery center

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Bernard Citron, Pr

Role: PRINCIPAL_INVESTIGATOR

University Hospital, Clermont-Ferrand

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Clermont-Ferrand University Hospital

Clermont-Ferrand, Auvergne, France

Site Status

Countries

Review the countries where the study has at least one active or historical site.

France

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHU63-0016

Identifier Type: -

Identifier Source: org_study_id